Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
LIVDELZI (SELADELPAR LYSINE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
LIVDELZI
NDA
Get alerts
SELADELPAR LYSINE | N217899 | GILEAD SCIENCES INC
1 strength
6 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
6 unique patents, 2 exclusivities by expiration date
Expiring < 1yr (2)
Active (4)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
2034
2035
Today
7301050
Aug. 2, 2026
7709682
Sep. 13, 2026
9486428
Mar. 19, 2035
10272058
Mar. 19, 2035
11406611
Mar. 19, 2035
11596614
Mar. 19, 2035
NCE
Aug. 14, 2029
ODE-486
Aug. 14, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 10MG BASE
RLD
6 patents
2 exclusivities
▴
CAPSULE;ORAL | Approved: Aug 14, 2024
Patents (6)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7301050
Aug 2, 2026
—
Yes
Yes
—
—
7709682
Sep 13, 2026
—
Yes
—
—
—
9486428
Mar 19, 2035
—
—
—
U-1854
TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
—
10272058
Mar 19, 2035
—
—
—
U-1854
TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
—
11406611
Mar 19, 2035
—
—
—
U-1854
TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
—
11596614
Mar 19, 2035
—
—
—
U-1854
TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
—
Exclusivities (2)
Code
Date
Status
NCE
Aug 14, 2029
Active
ODE-486
Aug 14, 2031
Active